Document is current
Any future updates will be listed below
-
Authors
Gossec, Laure https://orcid.org/0000-0002-4528-310X
Baraliakos, Xenofon https://orcid.org/0000-0002-9475-9362
Galloway, James https://orcid.org/0000-0002-1230-2781
Oke, Vilija https://orcid.org/0000-0002-1834-2688
Sfikakis, Petros https://orcid.org/0000-0001-5484-2930
Rampakakis, Emmanouil https://orcid.org/0000-0002-7427-8246
Sharaf, Mohamed https://orcid.org/0009-0003-9847-2996
Lavie, Frederic https://orcid.org/0000-0002-5213-257X
McInnes, Iain B. https://orcid.org/0000-0002-6462-4280
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03796858 at ClinicalTrials.govDocuments that mention this clinical trial
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
https://doi.org/10.1136/rmdopen-2022-002934
POS1038 GUSELKUMAB EFFICACY IN PSORIATIC ARTHRITIS ASSESSED BY MULTI-DOMAIN COMPOSITE INDICES: DATA FROM THE PHASE 3B COSMOS TRIAL IN A TNFi-IR POPULATION
https://doi.org/10.1136/annrheumdis-2022-eular.1792
Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study
https://doi.org/10.1007/s40744-025-00821-2
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial
https://doi.org/10.1136/rmdopen-2024-004494
POS0943 GUSELKUMAB PROVIDES DURABLE IMPROVEMENTS IN PAIN AMONG PATIENTS WITH PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNFi: COSMOS PHASE 3b TRIAL
https://doi.org/10.1136/annrheumdis-2024-eular.1198
AB1082 EARLY CLINICAL RESPONSE AS A PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND TNFI-IR RECEIVING GUSELKUMAB (COSMOS)
https://doi.org/10.1136/annrheumdis-2023-eular.359
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
https://doi.org/10.1136/annrheumdis-2021-220991
AB1111 SUSTAINED RESPONSE TO GUSELKUMAB REGARDLESS OF BASELINE DEMOGRAPHIC, DISEASE, AND MEDICATION CHARACTERISTICS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TNF INHIBITORS: RESULTS FROM A PHASE 3B TRIAL
https://doi.org/10.1136/annrheumdis-2023-eular.2264
-
Funding
Funding for this research was provided by:
Johnson and Johnson
- License Information
-
More Information
Article History
Received: 8 October 2025
Accepted: 10 December 2025
First Online: 23 January 2026
Declarations
:
: Laure Gossec: research grants: AbbVie, Eli Lilly, Novartis, UCB; consulting fees: AbbVie, AlfaSigma, Amgen, Bristol Myers Squibb, Celltrion, Eli Lilly, Johnson & Johnson, Moonlake, Novartis, Pfizer, Stada, UCB; non-financial support: AbbVie, Amgen, Biogen, Celltrion, Johnson & Johnson, Pfizer, UCB. Xenofon Baraliakos: speakers bureau: AbbVie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, and UCB; consultant of: AbbVie, Chugai, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Roche, and UCB; grant/research support: AbbVie, Eli Lilly, Johnson & Johnson, MSD, Novartis. James Galloway: consulting fees, grant/research support, and speakers bureau: AbbVie, Alfasigma, Eli Lilly, Galapagos, Johnson & Johnson, Novartis, Pfizer, and UCB. Vilija Oke: consulting fees: AbbVie, Eli Lilly, Johnson & Johnson, Novartis, AstraZeneca, and UCB. Research grant from ONO Pharma. Petros Sfikakis: consulting fees and grant/research support: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli-Lilly, Johnson & Johnson, Novartis, UCB, and Pfizer. Emmanouil Rampakakis: employee: JSS Medical Research; paid consultant of: Johnson & Johnson. Mohamed Sharaf: employee: Johnson & Johnson; shareholder of: Johnson & Johnson. Frederic Lavie: employee: Johnson & Johnson at the time this work was performed and currently an employee of Les Entreprises du Médicament, Paris, France; shareholder of Johnson & Johnson. Iain B. McInnes: consulting fees: AbbVie, Amgen, Astra Zeneca, Bristol Myers Squibb, Cabaletta, Compugen, Eli Lilly, Gilead, Glaxo Smith Kline, Johnson & Johnson, Novartis, Pfizer, Roche, Sanofi, and UCB; grant/research support: Amgen, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Novartis, Roche, and UCB; shareholder: Causeway, and Evelo Compugen; NHS GGC Board Member; Evelo Board of Directors; and Versus Arthritis Trustee.
: The COSMOS study was conducted in accordance with principles of the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice. Each site’s ethical body approved the study protocol, and all participants provided written informed consent.
